U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C15H14O6
Molecular Weight 290.2681
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CIANIDANOL, (±)-

SMILES

O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C3=CC=C(O)C(O)=C3

InChI

InChIKey=PFTAWBLQPZVEMU-DZGCQCFKSA-N
InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1

HIDE SMILES / InChI

Description

Cianidanol is an antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms. One of the polyphenols present in green tea, (+)-catechin (Cianidanol), has been studied for its effects on animal models of hepatitis, as well as in human clinical studies. Pure (+)-catechin (also known as (+)- cyanidanol-3 – trade name Catergen) has been used to treat hepatitis since 1976. This compound has been shown to be an efficient immune stimulator, promoting activation of macrophages, cytotoxic-T-lymphocytes, and natural killer cells in mice. Several clinical studies demonstrate the effectiveness of (+)-catechin in the treatment of viral hepatitis. Pure (+)-catechin has been found to cause hemolysis in some patients, possibly by the promotion of antibody formation against (+)-catechin, which might cross-react with red blood cells. However, there are no reports in the literature of green tea, green tea extracts, or green tea polyphenols causing this side-effect.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
93.3 µM [IC50]
36.7 µM [IC50]
13.1 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cianidanol
Preventing
Unknown
Primary
Unknown
Preventing
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
78.3 nM
35 mg single, oral
CIANIDANOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
306 nM × h
35 mg single, oral
CIANIDANOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
3.17 h
35 mg single, oral
CIANIDANOL plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
4.1%
CIANIDANOL plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Take 1~3 packet daily
Route of Administration: Oral
In Vitro Use Guide
The in vitro effect of the drug was assessed using cianidanol at 10(-6), 10(-5) and 10(-4) M concentrations.